Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus P Schlaich

Showing results (1-10 of 363) with videos related to

Pageof 37
Sort By:
Hypertension (Dallas, Tex. : 1979)|January 18, 2023
Time in Target Range: the Future of Assessing Adequacy of Blood Pressure Control?Markus P Schlaich
American Journal of Physiology. Renal Physiology|September 16, 2016
What we need to know about renal nerve ablation for treatment of hypertension and other states of sympathetic overactivityMarkus P Schlaich
Journal of Hypertension|March 3, 2016
Microalbuminuria--an important marker of residual risk: evidence from a primary care settingMarkus P Schlaich
Nature Reviews. Nephrology|February 26, 2014
Hypertension: treatment-resistant hypertension - a risk factor for ESRDMarkus P Schlaich
Hypertension (Dallas, Tex. : 1979)|February 9, 2011
Sympathetic activation in chronic kidney disease: out of the shadowMarkus P Schlaich
American Journal of Hypertension|March 25, 2017
Renal Sympathetic Denervation: A Viable Option for Treating Resistant HypertensionMarkus P Schlaich
Journal of Human Hypertension|January 12, 2018
May measurement month 2017-a concerted global effort to raise awareness of elevated blood pressureMarkus P Schlaich, Melinda Carrington
Journal of Cardiovascular Pharmacology and Therapeutics|January 8, 2016
The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney DiseaseYusuke Sata, Markus P Schlaich
Journal of Hypertension|August 12, 2010
Sympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander?Markus P Schlaich, Guido Grassi
International Journal of Hypertension|March 28, 2013
Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY StudyIrina Chazova, Markus P Schlaich
Pageof 37

Showing results (1-10 of 363) with videos related to

Sort By:
Pageof 37
Hypertension (Dallas, Tex. : 1979)|January 18, 2023
Time in Target Range: the Future of Assessing Adequacy of Blood Pressure Control?Markus P Schlaich
American Journal of Physiology. Renal Physiology|September 16, 2016
What we need to know about renal nerve ablation for treatment of hypertension and other states of sympathetic overactivityMarkus P Schlaich
Journal of Hypertension|March 3, 2016
Microalbuminuria--an important marker of residual risk: evidence from a primary care settingMarkus P Schlaich
Nature Reviews. Nephrology|February 26, 2014
Hypertension: treatment-resistant hypertension - a risk factor for ESRDMarkus P Schlaich
Hypertension (Dallas, Tex. : 1979)|February 9, 2011
Sympathetic activation in chronic kidney disease: out of the shadowMarkus P Schlaich
American Journal of Hypertension|March 25, 2017
Renal Sympathetic Denervation: A Viable Option for Treating Resistant HypertensionMarkus P Schlaich
Journal of Human Hypertension|January 12, 2018
May measurement month 2017-a concerted global effort to raise awareness of elevated blood pressureMarkus P Schlaich, Melinda Carrington
Journal of Cardiovascular Pharmacology and Therapeutics|January 8, 2016
The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney DiseaseYusuke Sata, Markus P Schlaich
Journal of Hypertension|August 12, 2010
Sympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander?Markus P Schlaich, Guido Grassi
International Journal of Hypertension|March 28, 2013
Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY StudyIrina Chazova, Markus P Schlaich
Pageof 37